Arbutus Biopharma Corp
Closed
4.35 -1.36
Overview
Share price change
24h
Min
4.35
Max
4.42
Income | 173M 170M |
|---|---|
Sales | 178M 179M |
P/E Sector Avg | 4.988 49.701 |
EPS | 1.194 |
Profit margin | 94.735 |
Employees | 19 |
EBITDA | 177M 169M |
Next Earnings | 5 Aug 2026 |
|---|
Market Cap | -47M 818M |
|---|---|
Previous open | 5.71 |
Previous close | 4.35 |
Arbutus Biopharma Corp Chart
Past performance is not a reliable indicator of future results.
Related News
Peer Comparison
Price change
Arbutus Biopharma Corp Forecast
Financials
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$
About Arbutus Biopharma Corp
Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection in the United States. Its HBV product pipeline consists of imdusiran (AB-729), a proprietary subcutaneously-delivered RNAi therapeutic product candidate that suppresses all HBV antigens, including HBsAg expression. The company's research and development programs include AB-101, an oral PD-L1 inhibitor to reawaken patients' HBV-specific immune system; and small molecule antiviral medicines to treat coronaviruses, including COVID-19. It has licensing agreements with Gritstone Oncology, Inc; Alnylam Pharmaceuticals, Inc.; Qilu Pharmaceuticals Co, Ltd; Assembly Biosciences, Inc.; Acuitas Therapeutics, Inc.; and Antios Therapeutics, Inc. Arbutus Biopharma Corporation also has a clinical collaboration agreement with Barinthus Biotherapeutics plc to evaluate VTP-300. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation is headquartered in Warminster, Pennsylvania.
